1101: Factors Associated with Clinical Evident Thromboembolic Events Following Nephrectomy

2006 ◽  
Vol 175 (4S) ◽  
pp. 354-354
Author(s):  
Joseph A. Pettus ◽  
Scott E. Eggener ◽  
Brent Yanke ◽  
Ahmad Shabsigh ◽  
Angel Serio ◽  
...  
Keyword(s):  
Thromboembolic Events ◽  
Factors Associated

scholarly journals Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Ting Wu ◽  
Zhihong Zuo ◽  
Deyi Yang ◽  
Xuan Luo ◽  
Liping Jiang ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Meta Analysis ◽  
Adverse Outcomes ◽  
Thromboembolic Events ◽  
Severe Condition ◽  
Factors Associated ◽  
Reactive Protein ◽  
Online Databases ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Abstract Background High incidence of venous thromboembolic complications in coronavirus disease 2019 (COVID-19) patients was noted recently. Objective This study aimed to explore the factors associated with prevalence of venous thromboembolism (VTE) in COVID-19 patients. Methods A literature search was conducted in several online databases. Fixed effects meta-analysis was performed for the factors associated with prevalence of VTE in COVID-19 patients. Results A total of 39 studies were analysed in this analysis. The incidence of pulmonary embolism and VTE in severe COVID-19 patients were 17% (95% CI, 13–21%) and 42% (95% CI, 25–60%), respectively. VTE were more common among individuals with COVID-19 of advance age. Male COVID-19 patients are more likely to experience VTE. Higher levels of white blood cell (WBC; WMD = 1.34 × 109/L; 95% CI, 0.84–1.84 × 109/L), D-dimer (WMD = 4.21 μg/ml; 95% CI, 3.77–4.66 μg/ml), activated partial thromboplastin time (APTT; WMD = 2.03 s; 95% CI, 0.83–3.24 s), fibrinogen (WMD = 0.49 μg/ml; 95% CI, 0.18–0.79 g/L) and C-reactive protein (CRP; WMD = 21.89 mg/L; 95% CI, 11.44–32.34 mg/L) were commonly noted in COVID-19 patients with VTE. Patients with lower level of lymphocyte (WMD = −0.15 × 109/L; 95% CI, −0.23-−0.07 × 109/L) was at high risk of developing VTE. The incidence of severe condition (OR = 2.66; 95% CI, 1.95–3.62) was more likely to occur among COVID-19 patients who developed VTE. Conclusion VTE is a common complication in severe COVID-19 patients and thromboembolic events are also associated with adverse outcomes.

Factors associated with thromboembolic events in patients with pulmonary tuberculosis

2020 ◽  
Author(s):  
Abir Hedhli Ep Cherni ◽  
Safa Marzouki ◽  
Meriem Mjid ◽  
Yacine Ouahchi ◽  
Sana Cheikhrouhou ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Thromboembolic Events ◽  
Factors Associated

Risk Factors Associated with Venous Thromboembolic Events in Patients with Malignancy.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2592-2592
Author(s):  
Jules Lin ◽  
Hang Li ◽  
Thomas W. Wakefield ◽  
Peter K. Henke
Keyword(s):  
Solid Tumors ◽  
Advanced Age ◽  
Thromboembolic Events ◽  
University Of Michigan ◽  
Vte Prophylaxis ◽  
Factors Associated ◽  
Increased Risk ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
The University

Abstract Malignancy is a major risk factor for venous thromboembolic events (VTE), but not all patients with malignancy develop this complication. Who best to aggressively prophylax is thus not well defined. In the current study, 960 consecutive patients, 523 men and 437 women, admitted to the University of Michigan with malignancy between 1992–2000 were identified using ICD-9CM codes. Factors including cancer stage, type, therapy, and patient vital status were obtained from a database maintained prospectively by the University of Michigan Cancer Registry as well as a review of the medical record. Acute VTE, confirmed on radiological or ultrasound studies, occurred in 408 patients and were compared to 552 patients who did not experience any VTE using logistic regression analysis. Factors associated with VTE include solid tumors (Odds Ratio 5.0; 95% confidence interval 1.65–14.9, P =.004), infection (4.9; 1.2–19.8, P =.025), and advanced age (1.05; 1.03–1.08, P <.001). Interestingly, while leukopenia (4.2; 1.23–14.6, P =.023) was associated with an increased incidence of VTE, neutropenia was not, suggesting that a deficiency of a different class of leukocytes is more important in predisposing to primary VTE. Neutropenia was associated with recurrent, but not primary VTE (P =.034). Type of therapy, gender, and stage were not associated with VTE. Kaplan Meier estimated survival was decreased in patients with VTE as compared to those without (3.3 vs. 3.7 years, P=.18). Factors associated with a decreased survival include solid tumors (3.9; 1.8–8.4, P <.01), infection (3.3; 1.1–9.9, P =.03), advanced stage (1.6; 1.2–2.1, P <.01), and increased age (1.02; 1.0–1.04, P =.01). Patients with solid tumors, advanced age, and leukopenia have a significantly increased risk of VTE and might benefit from aggressive VTE prophylaxis, whereas other patients with malignancy can probably be carefully observed.

Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

2017 ◽  
Vol 116 (7) ◽  
pp. 914-920 ◽  
Author(s):  
Amihai Rottenstreich ◽  
Yosef Kalish ◽  
Geffen Kleinstern ◽  
Almog Ben Yaacov ◽  
Joseph Dux ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Thromboembolic Events ◽  
Factors Associated

scholarly journals Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants

2020 ◽  
Author(s):  
Niklas Wallvik ◽  
Henrik Renlund ◽  
Anders Själander
Keyword(s):  
Risk Factors ◽  
Major Bleeding ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Thromboembolic Events ◽  
Cox Regression Analysis ◽  
Factors Associated ◽  
Previous Stroke ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Abstract New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulation register Auricula (during 2012.01.01–2017.12.31) to find patients and used other national registers for outcomes. Primary endpoint was major bleeding defined as bleeding leading to hospital care. Multivariate Cox-regression analysis was used to reveal risk factors. 18 219 patients with NOAC due to VTE were included. 85.6% had their first VTE, mean age was 69.4 years and median follow-up time was 183 days. The most common NOAC was rivaroxaban (54.8%), followed by apixaban (42.0%), dabigatran (3.2%) and edoxaban (0.1%). The rate of major bleeding was 6.62 (95% CI 6.19–7.06) per 100 treatment years in all patients and 11.27 (CI 9.96–12.57) in patients above 80 years of age. Statistically independent risk factors associated with major bleeding were age (normalized HR 1.38, CI 1.27–1.50), earlier major bleeding (HR 1.58, Cl 1.09–2.30), COPD (HR 1.28, CI 1.04–1.60) and previous stroke (HR 1.28, Cl 1.03–1.58) or transient ischemic attack (TIA) (HR 1.33, Cl 1.01–1.76). Prior warfarin treatment was protective (HR 0.67, CI 0.58–0.78). This real world cohort shows a high bleeding rate especially among the elderly and in patients with previous major bleeding, COPD and previous stroke or TIA. This should be considered when deciding on treatment duration and NOAC dose in these patients.

scholarly journals Risk Factors for Postoperative Venous Thromboembolic Events in Patients Undergoing Lumbar Spine Surgery

2018 ◽  
Vol 9 (4) ◽  
pp. 409-416 ◽  
Author(s):  
Alexander Nazareth ◽  
Anthony D’Oro ◽  
John C. Liu ◽  
Kyle Schoell ◽  
Patrick Heindel ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lumbar Spine ◽  
Spine Surgery ◽  
Lumbar Spine Surgery ◽  
Thromboembolic Events ◽  
Lumbar Surgery ◽  
Factors Associated ◽  
Patient Demographics ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Study Design: Retrospective, database study. Objectives: The aim of this study was to investigate incidence and risk factors associated with venous thromboembolic events (VTEs) after lumbar spine surgery. Methods: Patients who underwent lumbar surgery between 2007 and 2014 were identified using the Humana within PearlDiver database. ICD-9 (International Classification of Diseases Ninth Revision) diagnosis codes were used to search for the incidence of VTEs among surgery types, patient demographics and comorbidities. Complications including DVT and PE were queried each day from the day of surgery to postoperative day 7 and for periods 0 to 1 week, 0 to 1 month, 0 to 2 months, and 0 to 3 months postoperatively. Results: A total of 64 892 patients within the Humana insurance database received lumbar surgery between 2007 and 2014. Overall VTE rate was 0.9% at 1 week, 1.8% at 1 month, and 2.6% at 3 months postoperatively. Among patients that developed a VTE within 1 week postoperatively, 45.3% had a VTE on the day of surgery. Patients with 1 or more identified risk factors had a VTE incidence of 2.73%, compared with 0.95% for patients without risk factors ( P < .001). Risk factors associated with the highest VTE incidence and odds ratios (ORs) were primary coagulation disorder (10.01%, OR 4.33), extremity paralysis (7.49%, OR 2.96), central venous line (6.70%, OR 2.87), and varicose veins (6.51%, OR 2.58). Conclusions: This study identified several patient comorbidities that were independent predictors of postoperative VTE occurrence after lumbar surgery. Clinical VTE risk assessment may improve with increased focus toward patient comorbidities rather than surgery type or patient demographics.

scholarly journals Adverse Events Following International Normalized Ratio Reversal in Intracerebral Hemorrhage

2016 ◽  
Vol 42 (5-6) ◽  
pp. 446-454 ◽  
Author(s):  
Mona Laible ◽  
Ekkehart Jenetzky ◽  
Christopher Beynon ◽  
Oliver Josef Müller ◽  
Peter Sander ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Clinical Characteristics ◽  
Point Of Care ◽  
Vitamin K Antagonists ◽  
International Normalized Ratio ◽  
Thromboembolic Events ◽  
Prothrombin Complex Concentrates ◽  
Factors Associated ◽  
Before And After ◽  
High Doses

Background: Prothrombin complex concentrates (PCCs) are frequently used to reverse the effect of vitamin K antagonists (VKAs) in patients with non-traumatic intracerebral hemorrhage (ICH). However, information on the rate of thromboembolic events (TEs) and allergic events after PCC therapy in VKA-ICH patients is limited. Methods: Consecutive VKA-ICH patients treated with PCC at our institution between December 2004 and June 2014 were included into this retrospective observational study. We recorded international normalized ratio (INR) values before and after PCC treatment, baseline clinical characteristics including the premorbid modified Rankin Scale (pmRS) score, TE and allergic event that occurred during the hospital stay. All events were classified by 3 reviewers as being ‘related', ‘probably related', ‘possibly related', ‘unlikely related' or ‘not related' to treatment with PCC. To identify factors associated with TEs, log-rank analyses were applied. Results: Two hundred and five patients were included. Median INR was 2.8 (interquartile range (IQR) 2.2-3.8) before and 1.3 (IQR 1.2-1.4) after PCC treatment and a median of 1,500 IU PCC (IQR 1,000-2,500) was administered. Nineteen TEs were observed (9.3%); none were classified ‘related' but 9 were classified as ‘possibly' or ‘probably related' to PCC infusion (4.4%). One allergic reaction (0.5%), ‘unlikely related' to PCC, was observed. In the whole cohort, PCC doses >2,000-3,000 IU, ICH volumes >40 ml, National Institute of Health Stroke Scale values >10 and a pmRS >2 were associated with the development of TEs (p = 0.031, p = 0.034, p = 0.050 and p = 0.036, respectively). Conclusions: Overall, INR reversal with PCC appears safe. Though no clear relationship between higher PCC dosing and TEs was observed, PCC doses between >2,000 and 3,000 IU and higher morbidity at ICH onset were associated with TEs. Hence, individual titration of PCC to avoid exposure to unnecessarily high doses using point-of-care devices should be prospectively explored.

Sign in / Sign up

Export Citation Format

Share Document